The impact of antiretroviral therapy on AIDS and survival

Journal of HIV Therapy

Volumn 11, Issue 2, 2006, Pages 36-38

  Lundgren, Jens D ^a   Mocroft, Amanda ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INCIDENCE; MORTALITY; REVIEW; TREATMENT OUTCOME; VIROLOGY; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; HIV-1; HUMANS; INCIDENCE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33750139100     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. European AIDS Clinical Society treatment guidelines. http://www.eacs.ws/ guide/index.htm. Accessed 8 June 2006.
2. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://AIDSinfo.nih.gov. Accessed 8 June 2006.
3. Røge BT, Barfod TS, Kirk O et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med, 2004, 5, 344-351.
4. Gallant JE, Rodriguez AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis, 2005, 192, 1921-1930.
5. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA, 2001, 286, 2560-2567.
6. Clavel F and Hance AJ. HIV drug resistance. N Engl JMed, 2004, 350, 1023-1035.
7. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med, 2001, 344, 472-480.
8. Cozzi-Lepri A, Phillips AN, Miller V et al. Changes in viral load in people with virological failure who remain on the Same HAART regimen. Antivir Ther, 2003, 8, 127-136.
9. Ledergerber B, Lundgren JD, Walker AS et al for the PLATO collaboration. Predictors of trends in CD4 positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, 2004, 364, 51-62.
10. Lundgren JD, Mocroft A, Gatell JM et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis, 2002, 185, 178-187.
11. Olsen CH, Gatell J, Ledergerber B et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS, 2005, 19, 319-330.
12. Grossman Z, Meier-Schellersheim M, Paul WE and Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med, 2006, 12, 289-295.
13. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med, 2001, 344, 168-174.
14. Battegay Nuesch R, Hirschel B and Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis, 2006, 6, 280-287.
15. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med, 2000, 133, 401-410.
16. Mocroft A, Phillips AN, Ledergerber B et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS, 2006, 20, 1141-1150.
17. Viard JP, Mocroft A, Chiesi A et al. Influence of age on CD4 cell recovery in human immunodeficiency virus infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis, 2001, 183, 1290-1294.
18. Podlekareva D, Mocroft A, Dragsted UB et al. Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. J Infect Dis, 2006 (in press).
19. Mocroft A, Ledergerber B, Katlama C et al. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 2003, 362, 22-29.
20. Weber R, Sabin CA, Friis-Møller N et al. Liver-related deaths among persons infected with the human immunodeficiency virus: the D:A:D Study. Arch Intern Med, 2006 (in press).
21. El-Sadr W and Neaton J for the SMART study investigators. Episodic CD4 guided use of antiretroviral therapy is inferior to current therapy: results of the SMART study. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006, Abstr. 106LB.
22. Loomba R and Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther, 2006, 11, 1-15.
23. Matthews GV, Bartholomeusz A, Locarnini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIVHBV- infected individuals on extended lamivudine therapy. AIDS, 2006, 20, 863-870.
24. Puoti M, Cozzi-Lepri A, Paraninfo A et al. Impact of lamivudine on the risk of liver-related death in 2,041 HbsAg and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther, 2006 (in press).
25. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med, 2003, 349, 1993-2003.
26. French MA, Price P and Stone SF. Immune restoration disease after antiretroviral therapy. AIDS, 2004, 18, 1615-1627.
27. Phillips AN, Lepri AC, Lampe F et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS, 2003, 17, 1863-1869.